Cargando…
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Autores principales: | Oosting, Sjoukje F, van der Veldt, Astrid A M, Fehrmann, Rudolf S N, GeurtsvanKessel, Corine H, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, de Wilt, Faye, Boerma, Annemarie, van Zijl, Lisanne, Rimmelzwaan, Guus F, Kvistborg, Pia, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, de Vries, Elisabeth G E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236566/ https://www.ncbi.nlm.nih.gov/pubmed/35483383 http://dx.doi.org/10.1016/S1470-2045(22)00203-0 |
Ejemplares similares
-
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
por: Oosting, Sjoukje F, et al.
Publicado: (2021) -
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
por: van der Veldt, A.A.M., et al.
Publicado: (2023) -
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
por: Oosting, S.F., et al.
Publicado: (2023) -
LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
por: Oosting, S., et al.
Publicado: (2021) -
Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
por: Sanders, Jan-Stephan F, et al.
Publicado: (2022)